Thuya Aye, MD
Family Medicine · Dover, DENPI 1689831216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 25.9% of the total. Among family medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$668
- Astellas Pharma US Inc$426
- Pfizer$397
- AbbVie$393
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,33797%
- Education$1893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $1,952 |
| Novo Nordisk | 128 | $1,167 |
| Lilly USA, LLC | 44 | $668 |
| Astellas Pharma US Inc | 26 | $426 |
| Pfizer | 32 | $397 |
| AbbVie(2 entities) | 33 | $393 |
| GSK | 20 | $351 |
| Biohaven Pharmaceutical Holding Company Ltd. | 34 | $296 |
| Exact Sciences | 12 | $267 |
| Bayer | 13 | $251 |
| Johnson & Johnson | 9 | $190 |
| Biohaven Pharmaceuticals, Inc. | 19 | $168 |
| Dexcom, Inc. | 8 | $161 |
| Boehringer Ingelheim | 7 | $123 |
| Merck | 7 | $122 |
| Amgen | 7 | $111 |
| Abbott | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Eisai Inc. | 3 | $46 |
| Novartis | 2 | $38 |
| Shield Therapeutics Inc | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Verona Pharma, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,526 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $140,597 |
| JardianceEmpagliflozin | 109 | $136,253 |
| TrulicityDulaglutide | 76 | $96,903 |
| EliquisApixaban | 57 | $67,676 |
| FarxigaDapagliflozin Propanediol | 52 | $62,021 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $39,094 |
| MounjaroTirzepatide | 21 | $34,092 |
| TradjentaLinagliptin | 22 | $33,317 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $20,592 |
| JanuviaSitagliptin Phosphate | 13 | $18,722 |
| MyrbetriqMirabegron | 17 | $18,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $17,783 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $17,171 |
| XareltoRivaroxaban | 16 | $14,534 |
| Atorvastatin Calcium | 797 | $12,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $123 | $169,569131 claims |
| Novo NordiskOzempic | $1,167 | $140,59775 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $668 | $130,99597 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,952 | $101,11491 claims |
| PfizerEliquis | $397 | $67,67657 claims |
| MerckJanuvia, Janumet Xr | $122 | $35,89224 claims |
| Astellas Pharma US IncMyrbetriq | $426 | $18,14817 claims |
| GSKTrelegy Ellipta | $351 | $17,78322 claims |
| Johnson & JohnsonXarelto | $190 | $14,53416 claims |
| AbbVieUbrelvy | $393 | $11,64812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.
Other family medicine in Dover
- Nadiene HaynesDover$10K
- Lawrence LewandowskiDover$7K
- Brian HornDover$3K
- Kenny VuDover$3K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.